Journal article
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials
Abstract
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms are frequently driven by type 2 inflammation. Depemokimab is the first ultra-long-acting biological drug engineered with enhanced interleukin-5 binding affinity, high potency, and an extended half-life, enabling twice per year dosing and sustained type 2 inflammation inhibition. The ANCHOR-1 and ANCHOR-2 trials investigated the efficacy and safety of depemokimab in people …
Authors
Gevaert P; Desrosiers M; Cornet M; Mullol J; De Corso E; Turel NK; Maspero J; Fujieda S; Zhang L; Sousa AR
Journal
The Lancet, Vol. 405, No. 10482, pp. 911–926
Publisher
Elsevier
Publication Date
3 2025
DOI
10.1016/s0140-6736(25)00197-7
ISSN
0140-6736